Monitoring Patients on Methotrexate Therapy
Standard Monitoring Schedule
- For patients on stable methotrexate therapy, complete blood count (CBC), liver function tests (LFTs), and renal function tests should be performed every 3-4 months, not every 6 months, as recommended by the American College of Rheumatology 1, 2, 3
- CBC with differential, LFTs (ALT, AST), and renal function tests (creatinine, BUN) should be obtained within the first 1-2 months after starting methotrexate or after any dose increase 1, 2, 3
- The American Academy of Dermatology recommends monitoring liver function every 3-6 months for psoriasis patients 5, 6
Specific Tests to Include
- Complete blood count with differential to monitor for leukopenia, thrombocytopenia, and anemia 1, 2
- Liver enzymes (ALT, AST) to detect hepatotoxicity 1, 2, 3
- Serum creatinine and BUN to assess renal function 1, 2
Additional Monitoring for High-Risk Patients
- Fibrosis-4 (FIB-4) Index annually for patients with risk factors for liver disease (obesity, diabetes, alcohol use, pre-existing liver disease) 5, 3
Critical Timing Considerations
- Avoid testing within 2 days after the weekly methotrexate dose, as transient LFT elevations may occur and lead to unnecessary interventions 2
Management of Abnormal Results
- ALT/AST 2-3× upper limit of normal: Recheck in 2-4 weeks 4, 5
- ALT/AST >3× upper limit of normal: Decrease or temporarily hold methotrexate 4, 1, 2
- Persistent elevations >3× upper limit of normal: Discontinue methotrexate 4
- Significant drop in blood counts: Hold methotrexate immediately and consider leucovorin (folinic acid) rescue 1, 2, 3
Essential Preventive Measures
- Folic acid supplementation (1-5 mg daily, except on methotrexate dosing day) is strongly recommended to reduce hematologic and hepatic adverse effects 1, 2, 3